首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1672781

生物製藥和生物醫藥市場：按產品類型、應用、類型、給藥途徑、患者人口統計和地區分類

Biopharmaceutical and Biomedicine Market, By Product Type, By Application, By Type, By Route of Administration, By Patient Demographics, By Geography

出版日期: 2025年02月06日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球生物製藥和生物醫藥市場規模估計為 6,4026 億美元，預計到 2032 年將達到 14,251.7 億美元，2025 年至 2032 年的複合年成長率為 12.1%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	6402.6億美元
效能資料	從 2020 年到 2024 年	預測期	2025 至 2032 年
預測期：2025-2032年複合年成長率：	12.10％	2032 年價值預測	14,251.70億美元

數字。 2025 年生物製藥和生物醫藥市場區域佔有率（%）

過去幾十年來，全球生物製藥和生物醫藥市場經歷了顯著的成長。公共和私營部門不斷增加對研發活動的投資，推動了生技藥品、基因工程和開發新藥領域的突破性創新。細胞和基因治療、再生醫學、單株抗體和個人化醫療等領域的進步為治療慢性和危及生命的疾病提供了光明的前景。人口快速老化以及全球癌症、糖尿病和神經系統疾病盛行率的上升推動了對更有效治療方案的需求。此外，合成生物學和基因工程的重大進展使科學家能夠設計和開發先進的生技藥品，如疫苗、荷爾蒙和血液成分，在醫療保健和其他工業領域具有重要應用。儘管成長機會仍然巨大，但高昂的研發成本和嚴格的法規仍然是個挑戰。

市場動態：

推動全球生物製藥和生物醫藥市場成長的關鍵因素包括慢性病和文明病的盛行率上升、易患各種健康問題的老年人口快速增加以及對優質醫療產品和服務的需求不斷增加。此外，公私部門對先進蛋白質工程、重組DNA技術和幹細胞研究的大量投資促進了新型生物藥品和治療方法的開發。然而，從臨床試驗到核准的藥物開發成本極高，再加上敏感的製造流程和嚴格的法律規範，繼續限制市場的快速擴張。同時，個人化醫療和組織器官3D生物列印的日益關注也為市場發展帶來了新的途徑。此外，研究機構和產業參與者之間的夥伴關係有助於加快有前景的候選藥物的商業化並降低生產成本。

本研究的主要特點

本報告對全球生物製藥和生物醫藥市場進行了詳細分析，並展示了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），以 2024 年為基準年。

它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，對全球生物製藥和生物醫藥市場的主要企業進行分析。

主要企業包括諾華公司、強生公司、輝瑞公司、賽諾菲公司、禮來公司、羅氏公司、艾伯維公司、百時美施貴寶公司、Qiagen NV、Affimed NV、新基公司、安進公司、默克公司、葛蘭素史克公司和再生元製藥公司。

本報告的見解將幫助負責人和企業經營團隊就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

相關人員將透過用於分析全球生物製藥和生物醫藥市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 640.26 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	12.10%	2032 Value Projection:	USD 1,425.17 Bn

The global biopharmaceutical and biomedicine market has witnessed tremendous growth over the past few decades. Rising investment in research and development activities by both public and private sectors has led to path breaking innovations in the field of biologics, genetic engineering and novel drug development. Advancements in areas such as cell and gene therapy, regenerative medicine, monoclonal antibodies and personalized medicine holds promising prospects for the treatment of chronic and life-threatening diseases. Rapidly aging population and growing incidence of cancer, diabetes and neurological disorders globally has spurred demand for more effective therapeutic options. Moreover, substantial progress in synthetic biology and genetic engineering is allowing scientists to design and develop advanced biologics like vaccines, hormones and blood components, with significant applications in healthcare and other industrial verticals. While growth opportunities remain vast, high R&D costs and stringent regulatory framework continue posing challenges.

Market Dynamics:

The key factors driving the growth of global biopharmaceutical and biomedicine market include rising prevalence of chronic and lifestyle diseases, rapid increase in geriatric population susceptible to various health issues, growing demand for superior healthcare products and services. Moreover, heavy investments by both public and private players in advanced protein engineering, recombinant DNA technology and stem cell research have enabled development of novel biologic drugs and therapies. However, extremely high costs associated with drug development from clinical trial to approval, coupled with delicate manufacturing processes and stringent regulatory oversight continue to restrain faster market expansion. At the same time, growing focus on personalized medicine and 3D bioprinting of tissues and organ present new avenues for market progress. In addition, partnerships between research institutes and industry players are helping accelerate commercialization of promising drug candidates and lower production costs.

Key Features of the Study:

This report provides in-depth analysis of the global biopharmaceutical and biomedicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global biopharmaceutical and biomedicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb, Qiagen N.V., Affimed N.V., Celgene Corporation, Amgen Inc., Merck & Co., Inc., GSK Plc, and Regeneron Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceutical and biomedicine market

Market Segmentation

Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Biopharmaceuticals
- Monoclonal Antibodies
- Vaccines
- Recombinant Human Insulin
- Human Growth Hormone
- Erythropoietin
- Interferon
- Colony Stimulating Factor
- Blood Factors
- Fusion Protein
- Others
- Nanomedicine
- Cell & Gene Therapy
- Bioinformatics
- Molecular Enzymes & Kits
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Therapeutics
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Diseases
- Immune Disorders
- Diagnostics
- In Vitro Diagnostics
- In Vivo Diagnostics
- Point-of-Care Testing
- Research and Development
- Preclinical Research
- Clinical Trials
- Biotechnology Research
- Regulatory Research
Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded Biopharmaceuticals
- Generic Biopharmaceuticals
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Pediatric
- Geriatric
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis AG
- Johnson & Johnson
- Pfizer, Inc.
- Sanofi S.A.
- Eli Lilly and Company
- Hoffmann-La Roche AG
- AbbVie Inc.
- Bristol-Myers Squibb
- Qiagen N.V.
- Affimed N.V.
- Celgene Corporation
- Amgen Inc.
- Merck & Co., Inc.
- GSK Plc
- Regeneron Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Biopharmaceutical and Biomedicine Market, By Product Type
- Global Biopharmaceutical and Biomedicine Market, By Application
- Global Biopharmaceutical and Biomedicine Market, By Type
- Global Biopharmaceutical and Biomedicine Market, By Route of Administration
- Global Biopharmaceutical and Biomedicine Market, By Patient Demographics
- Global Biopharmaceutical and Biomedicine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Biopharmaceutical and Biomedicine Market, By Product Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biopharmaceuticals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Monoclonal Antibodies
- Vaccines
- Recombinant Human Insulin
- Human Growth Hormone
- Erythropoietin
- Interferon
- Colony Stimulating Factor
- Blood Factors
- Fusion Protein
- Others
Nanomedicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cell & Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bioinformatics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Molecular Enzymes & Kits
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Biopharmaceutical and Biomedicine Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Diseases
- Immune Disorders
Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- In Vitro Diagnostics
- In Vivo Diagnostics
- Point-of-Care Testing
Research and Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Preclinical Research
- Clinical Trials
- Biotechnology Research
- Regulatory Research

6. Global Biopharmaceutical and Biomedicine Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Branded Biopharmaceuticals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic Biopharmaceuticals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Biopharmaceutical and Biomedicine Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Biopharmaceutical and Biomedicine Market, By Patient Demographics, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Biopharmaceutical and Biomedicine Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa

10. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
Pfizer, Inc.
Sanofi S.A.
Eli Lilly and Company
F.Hoffmann-La Roche AG
AbbVie Inc.
Bristol-Myers Squibb
Qiagen N.V.
Affimed N.V.
Celgene Corporation
Amgen Inc.
Merck & Co., Inc.
GSK Plc
Regeneron Pharmaceuticals